The number of circulating monocytes as biomarkers of the clinical response to methotrexate in untreated patients with rheumatoid arthritis

• Published in: Journal of translational medicine 2015-01, Vol.13 (1), p.2-2, Article 2
• Main Authors: Chara, Luis, Sánchez-Atrio, Ana, Pérez, Ana, Cuende, Eduardo, Albarrán, Fernando, Turrión, Ana, Chevarria, Julio, del Barco, Angel Asunsolo, Sánchez, Miguel A, Monserrat, Jorge, Prieto, Alfredo, de la Hera, Antonio, Sanz, Ignacio, Diaz, David, Alvarez-Mon, Melchor
• Format: Article
• Language: English
• Subjects: Analysis; Antigens, CD - metabolism; Arthritis; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - pathology; Biomarkers - metabolism; Care and treatment; Case-Control Studies; Cell Count; Cell Movement; CX3C Chemokine Receptor 1; Demography; Diagnosis; Female; Health aspects; Humans; Male; Methotrexate; Methotrexate - pharmacology; Methotrexate - therapeutic use; Middle Aged; Monocytes - metabolism; Receptors, Chemokine - metabolism; Rheumatoid factor; ROC Curve; Treatment Outcome
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-014-0375-y

The aim of this work was to analyze the number and distribution of circulating monocytes, and of their CD14(+high)CD16(-), CD14(+high)CD16(+) and CD14(+low)CD16(+) subset cells, in treatment-naive patients with rheumatoid arthritis (RA), and to determine their value in predicting the clinical response to methotrexate (MTX) treatment. This prospective work investigated the number of circulating monocytes, and the numbers of CD14(+high)CD16(-), CD14(+high)CD16(+) and CD14(+low)CD16(+) subset cells, in 52 untreated patients with RA before MTX treatment, and at 3 and 6 months into treatment, using flow cytometry. The absolute number of circulating monocytes, and the numbers of CD14(+high)CD16(-), CD14(+high)CD16(+) and CD14(+low)CD16(+) subset cells, were significantly higher in MTX non-responders than in responders and healthy controls before starting and throughout treatment. Responders showed normal numbers of monocytes, and of their subset cells, over the study period. The pre-treatment absolute number of circulating monocytes, and the numbers of CD14(+high)CD16(-) and CD14(+high)CD16(+) subset cells, were found to be predictive of the clinical response to MTX, with a sensitivity and specificity of >70% and >88%, respectively. Treatment-naive patients with RA showed an anomalous distribution of circulating monocyte subsets, and an anomalous number of cells in each subset. A higher pre-treatment number of circulating monocytes, and higher numbers of CD14(+high)CD16(-) and CD14(+high)CD16(+) subset cells, predict a reduced clinical response to MTX in untreated patients with RA.